[1] |
LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan.
Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications
[J]. China Oncology, 2024, 34(4): 368-379.
|
[2] |
LI Xinran, LIANG Yiyi, TU Hong.
Research progress of the intratumoral microbiome
[J]. China Oncology, 2023, 33(9): 866-873.
|
[3] |
ZHANG Shaoqiu, YAN Li, LI Ruichen, ZHAO Yang, WANG Xiaoshen, YANG Xuguang, ZHU Yi.
Recent advances and prospect in immune microenvironment and its mechanisms of function in head and neck squamous cell carcinoma
[J]. China Oncology, 2023, 33(6): 629-636.
|
[4] |
ZUO Xueliang, CHEN Zhiqiang, DONG Runyu, WANG Zhixiong, CAI Juan.
The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor
[J]. China Oncology, 2023, 33(5): 460-468.
|
[5] |
YANG Wenxiao, GUO Linwei, LING Hong, HU Xin.
Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
[J]. China Oncology, 2023, 33(5): 484-498.
|
[6] |
GAO Heli, XU Jin, CHEN Jie, YU Xianjun.
Updates on precision medicine of pancreatic neuroendocrine tumor
[J]. China Oncology, 2023, 33(11): 993-1001.
|
[7] |
YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie.
Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer
[J]. China Oncology, 2023, 33(10): 945-953.
|
[8] |
LIU Xueping, MU Nai, LI Xiaochun, WANG Ruisi, TAN Bangxian.
Gingival metastasis from primary hepatocellular carcinoma: a case report
[J]. China Oncology, 2023, 33(1): 78-80.
|
[9] |
LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie.
Updates on medical treatment for neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 757-764.
|
[10] |
WANG Xianze, WU Wenming.
Evolution in the surgical treatment concepts of pancreatic neuroendocrine tumors
[J]. China Oncology, 2022, 32(9): 765-771.
|
[11] |
CUI Lingjun, TIAN Chao, CHENG Zixuan, ZHENG Jiabin, SU Fei, TAN Huangying.
Advances in preclinical research models for gastroenteropancreatic neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 779-785.
|
[12] |
YU Hang, LIU Wensheng, ZHANG Ning, LIU Haikuan, CHEN Luohai, YAO Wang, FAN Wenzhe, LI Jiaping, CHEN Jie, WANG Yu.
The efficacy and safety analysis of transarterial embolization in the treatment of cystic neuroendocrine neoplasm liver metastasis
[J]. China Oncology, 2022, 32(9): 794-799.
|
[13] |
ZHENG Xiuli, YAO Zhiyuan, WU Mingli, ER Limian, LI Shengmian.
Analysis of risk factors of lymph node metastasis and comparison of endoscopic resection methods in rectal neuroendocrine neoplasm
[J]. China Oncology, 2022, 32(9): 800-806.
|
[14] |
WANG Jian, DING Congcong, LU Yan, LI Tong.
NLK inhibits the transformation from prostatitis to prostate cancer through maintaining NF-κB/P53 functional balance
[J]. China Oncology, 2022, 32(7): 614-623.
|
[15] |
Society of Neuroendocrine Neoplasm of China Anti-Cancer Association.
China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasm (2022 edition)
[J]. China Oncology, 2022, 32(6): 545-579.
|